AIM： To study the immunological protective effect of H pylori vaccine with chitosan as an adjuvant and its mechanism. METHODS： Female BALB/c mice were randomly divided into seven groups and orally immunized respecti...AIM： To study the immunological protective effect of H pylori vaccine with chitosan as an adjuvant and its mechanism. METHODS： Female BALB/c mice were randomly divided into seven groups and orally immunized respectively with PBS, chitosan solution, chitosan particles, H pylori antigen, H pylori antigen plus cholera toxin （CT）, H pylori antigen plus chitosan solution, Hpylori antigen plus chitosan particles once a week for four weeks. Four weeks after the last immunization, the mice were challenged twice by alive Hpylori （1 × 10^9 CFU/mL） and sacrificed. Part of the gastric mucosa was embedded in paraffin, cut into sections and assayed with Giemsa staining. Part of the gastric mucosa was used to quantitatively culture Hpylori. EUSA was used to detect cytokine level in gastric mucosa and anti- Hpylori IgG1, IgG2a levels in serum. RESULTS： In the groups with chitosan as an adjuvant, immunological protection was achieved in 60% mice, which was significantly higher than in groups with H pylori antigen alone and without H pylori antigen （P 〈 0.05 or 0.001）. Before challenge, the level of IFN and IL-12 in gastric mucosa was significantly higher in the groups with chitosan as an adjuvant than in the control group and the group without adjuvant （P 〈 0.05 or 0.005）. After challenge, the level of IFN and IL-12 was significantly higher in the groups with adjuvant than in the groups without adjuvant and antigen （P 〈 0.05 or 0.001）. Before challenge, the level of IL-2 in gastric mucosa was not different among different groups. After challenge the level of IL-2 was significantly higher in the groups with adjuvant than in the control group （P 〈 0.05 or 0.001）. Before challenge, the level of IL-10 in gastric mucosa was significantly higher in the groups with chitosan as an adjuvant than in other groups without adjuvant （P 〈 0.05 or 0.01）. After challenge, the level of IL-10 was not different among different groups. Before challenge, the level of IL-4 in gastric mucosa was significantly higher in the groups with chitosan as an adjuvant than in other groups without adjuvant （P 〈 0.05）. After challenge, the level of IL-4 was significantly higher in the groups with chitosan particles as an adjuvant than in the group with CT as an adjuvant （P 〈 0.05）, and in the group with chitosan solution as an adjuvant, the level of IL-4 was significantly higher than that in control group, non-adjuvant group and the groups with CT （P 〈 0.05 or 0.001）. The ratio of anti- Hpylori IgG2a/ IgG1 in serum was significantly lower in the groups with chitosan as an adjuvant than in the groups with CT as an adjuvant or without adjuvant （P 〈 0.01）. CONCLUSION： H pylori vaccine with chitosan as an adjuvant can protect against H pylori infection and induce both Thl and Th2 type immune response.展开更多
An effective vaccine against group A streptococcus(GAS)is highly desirable for definitive control of GAS infections.In the present study,two variants of amphiphilic chitosan nanoparticles-based GAS vaccines were devel...An effective vaccine against group A streptococcus(GAS)is highly desirable for definitive control of GAS infections.In the present study,two variants of amphiphilic chitosan nanoparticles-based GAS vaccines were developed.The vaccines were primarily composed of encapsulated KLH protein(a source of T helper cell epitopes)and lipidated M-protein derived B cell peptide epitope(lipoJ14)within the amphiphilic structure of nanoparticles.The only difference between themwas one of the nanoparticles vaccines received additional surface coating with poly(I:C).The formulated vaccines exhibited nanosized particles within the range of 220–240 nm.Cellular uptake study showed that nanoparticles vaccine without additional poly(I:C)coating has greater uptake by dendritic cells and macrophages compared to nanoparticles vaccine that was functionalized with poly(I:C).Both vaccines were found to be safe in mice and showed negligible cytotoxicity against HEK293 cells.Upon immunization in mice,both nanoparticle vaccines produced high antigen-specific antibodies titres that were regulated by a balanced Th1 and Th2 response compared to physical mixture.These antibodies elicited high opsonic activity against the tested GAS strains.Overall,our data demonstrated that amphiphilic chitosan nanoparticles platform induced a potent immune response even without additional inclusion of poly(I:C).展开更多
In order to enhance the mucosal immunity of anti-caries DNA vaccine, chitosan-DNA microparticles for musocal vaccination were prepared by a coacervation method. The physicochemical structure of microparticles was inve...In order to enhance the mucosal immunity of anti-caries DNA vaccine, chitosan-DNA microparticles for musocal vaccination were prepared by a coacervation method. The physicochemical structure of microparticles was investigated by a scanning electron microscope (SEM) and a cofocal laser scanning microscope (CLSM). For in-vitro studies, Hela cell was transfected by chitosan-DNA microparticles.The expression of proteins was measured by the immunohistochemical methods, and the cytotocity of chitosan in Hela cell line was determined by the MTT assay. The experimental results show that the microparticles are about 2-6 μm in size and spherical in shape. The encapsulation efficiency is 99%, and the DNA is almost captured in the micropraticles. Plasmid loaded into chitosan microparticles is distributed throughout these particles. The number of positive staining cells of chitosan-pGJA-P transfected cell is more than that of naked plasmid transfect cells, but less than that of Lipofect-DNA complex group. Chitosan was found to be less cytotoxic compared with lipofectin (p<0.01).展开更多
We construct MUC1 vaccines usingβ-cyclodextrin grafted chitosan(CS-g-CD)as carrier via host-guest interaction.These vaccines based on non-covalent assembling can provoke robust immune responses,including high level o...We construct MUC1 vaccines usingβ-cyclodextrin grafted chitosan(CS-g-CD)as carrier via host-guest interaction.These vaccines based on non-covalent assembling can provoke robust immune responses,including high level of specific antibodies and cytokines.The induced antibodies can specifically recognize tumor cells and mediate cytotoxicity against tumor cells.These results indicate that CS-g-CD with strong immunostimulatory activities can be a straightforward platform for peptide-based vaccine construction.展开更多
基金Supported by Natural Science Foundation of Jiangxi Province (No.30460052)Program of Jiangxi Provincial Leaders in Their Chosen Field of Learning,No. K010501
文摘AIM： To study the immunological protective effect of H pylori vaccine with chitosan as an adjuvant and its mechanism. METHODS： Female BALB/c mice were randomly divided into seven groups and orally immunized respectively with PBS, chitosan solution, chitosan particles, H pylori antigen, H pylori antigen plus cholera toxin （CT）, H pylori antigen plus chitosan solution, Hpylori antigen plus chitosan particles once a week for four weeks. Four weeks after the last immunization, the mice were challenged twice by alive Hpylori （1 × 10^9 CFU/mL） and sacrificed. Part of the gastric mucosa was embedded in paraffin, cut into sections and assayed with Giemsa staining. Part of the gastric mucosa was used to quantitatively culture Hpylori. EUSA was used to detect cytokine level in gastric mucosa and anti- Hpylori IgG1, IgG2a levels in serum. RESULTS： In the groups with chitosan as an adjuvant, immunological protection was achieved in 60% mice, which was significantly higher than in groups with H pylori antigen alone and without H pylori antigen （P 〈 0.05 or 0.001）. Before challenge, the level of IFN and IL-12 in gastric mucosa was significantly higher in the groups with chitosan as an adjuvant than in the control group and the group without adjuvant （P 〈 0.05 or 0.005）. After challenge, the level of IFN and IL-12 was significantly higher in the groups with adjuvant than in the groups without adjuvant and antigen （P 〈 0.05 or 0.001）. Before challenge, the level of IL-2 in gastric mucosa was not different among different groups. After challenge the level of IL-2 was significantly higher in the groups with adjuvant than in the control group （P 〈 0.05 or 0.001）. Before challenge, the level of IL-10 in gastric mucosa was significantly higher in the groups with chitosan as an adjuvant than in other groups without adjuvant （P 〈 0.05 or 0.01）. After challenge, the level of IL-10 was not different among different groups. Before challenge, the level of IL-4 in gastric mucosa was significantly higher in the groups with chitosan as an adjuvant than in other groups without adjuvant （P 〈 0.05）. After challenge, the level of IL-4 was significantly higher in the groups with chitosan particles as an adjuvant than in the group with CT as an adjuvant （P 〈 0.05）, and in the group with chitosan solution as an adjuvant, the level of IL-4 was significantly higher than that in control group, non-adjuvant group and the groups with CT （P 〈 0.05 or 0.001）. The ratio of anti- Hpylori IgG2a/ IgG1 in serum was significantly lower in the groups with chitosan as an adjuvant than in the groups with CT as an adjuvant or without adjuvant （P 〈 0.01）. CONCLUSION： H pylori vaccine with chitosan as an adjuvant can protect against H pylori infection and induce both Thl and Th2 type immune response.
基金supported financially by Universiti Kebangsaan Malaysia(UKM),Malaysia[DCP-2017-003/2].
文摘An effective vaccine against group A streptococcus(GAS)is highly desirable for definitive control of GAS infections.In the present study,two variants of amphiphilic chitosan nanoparticles-based GAS vaccines were developed.The vaccines were primarily composed of encapsulated KLH protein(a source of T helper cell epitopes)and lipidated M-protein derived B cell peptide epitope(lipoJ14)within the amphiphilic structure of nanoparticles.The only difference between themwas one of the nanoparticles vaccines received additional surface coating with poly(I:C).The formulated vaccines exhibited nanosized particles within the range of 220–240 nm.Cellular uptake study showed that nanoparticles vaccine without additional poly(I:C)coating has greater uptake by dendritic cells and macrophages compared to nanoparticles vaccine that was functionalized with poly(I:C).Both vaccines were found to be safe in mice and showed negligible cytotoxicity against HEK293 cells.Upon immunization in mice,both nanoparticle vaccines produced high antigen-specific antibodies titres that were regulated by a balanced Th1 and Th2 response compared to physical mixture.These antibodies elicited high opsonic activity against the tested GAS strains.Overall,our data demonstrated that amphiphilic chitosan nanoparticles platform induced a potent immune response even without additional inclusion of poly(I:C).
文摘In order to enhance the mucosal immunity of anti-caries DNA vaccine, chitosan-DNA microparticles for musocal vaccination were prepared by a coacervation method. The physicochemical structure of microparticles was investigated by a scanning electron microscope (SEM) and a cofocal laser scanning microscope (CLSM). For in-vitro studies, Hela cell was transfected by chitosan-DNA microparticles.The expression of proteins was measured by the immunohistochemical methods, and the cytotocity of chitosan in Hela cell line was determined by the MTT assay. The experimental results show that the microparticles are about 2-6 μm in size and spherical in shape. The encapsulation efficiency is 99%, and the DNA is almost captured in the micropraticles. Plasmid loaded into chitosan microparticles is distributed throughout these particles. The number of positive staining cells of chitosan-pGJA-P transfected cell is more than that of naked plasmid transfect cells, but less than that of Lipofect-DNA complex group. Chitosan was found to be less cytotoxic compared with lipofectin (p<0.01).
基金supported by the National Natural Science Foundation of China(Nos.21907038 and 32000904)Natural Science Foundation of Jiangsu Province(No.BK20200601)+5 种基金National Postdoctoral Program for Innovative Talents of China(No.BX20200153)China Postdoctoral Science Foundation(Nos.2018M632227 and2021M691293)the Social Development Key Project of Jiangsu Province(No.BE2019632)the Health and Family Planning Commission of Wuxi,China(No.Z202005)Suzhou People’s Livelihood Science and Technology Project,China(No.SYS2018100)supported by the 111 Project(No.111-2-06)。
文摘We construct MUC1 vaccines usingβ-cyclodextrin grafted chitosan(CS-g-CD)as carrier via host-guest interaction.These vaccines based on non-covalent assembling can provoke robust immune responses,including high level of specific antibodies and cytokines.The induced antibodies can specifically recognize tumor cells and mediate cytotoxicity against tumor cells.These results indicate that CS-g-CD with strong immunostimulatory activities can be a straightforward platform for peptide-based vaccine construction.
